Advanced or Recurrent Ovarian, Cervical, and Endometrial Cancer Treated With SHetA2
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test the safety of the study drug (SHetA2) and see what
effects (good and bad) this drug has on patients with recurrent cervical, ovarian, or
endometrial cancer.